1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search results consecutively by pressing the navigational buttons
(
<
1 of
13
>).
Within the text the search result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
In the first quarter of 2013, the Merck Serono division maintained the strong momentum of the previous quarters. Total revenues increased by 3.5% to € 1,548 million (Q1 2012: € 1,495 million). This reflected robust organic growth of 4.9% and a decline of 1.4% due to changes in foreign exchange rates. The division’s sales rose by 2.6% to € 1,454 million (Q1 2012: € 1,417 million) resulting from organic growth of 4.0% and a negative exchange rate impact of –1.4%. In addition to the division’s two top-selling products, Rebif® for the treatment of multiple sclerosis (MS) as well as the cancer therapy Erbitux®, the diabetes treatment Glucophage® was one [...]
The Performance Materials division continued its dynamic development of the preceding quarters. Reported sales increased by 9.0% to € 421 million (Q1 2012: € 386 million). While sales grew organically by 9.9%, changes in foreign exchange rates, especially relative to the Japanese yen, lowered sales by 0.9 percentage points, an impact not seen for several quarters. Higher sales volumes of liquid crystal materials recorded in the Liquid Crystals business unit were the main driver of the strong organic growth rate, more than offsetting price declines due to competitive pressure and volume rebates. In particular, demand for liquid crystals based on [...]
In the first quarter of 2013, Merck Millipore’s sales increased 2.5% to € 669 million (Q1 2012: € 653 million). While organically sales were up 3.6%, changes in foreign exchange rates had an adverse impact of 1.6%. Last year’s acquisition of Biochrom had a positive impact of 0.5%. Royalty, licence and commission income more than doubled to € 6 million (Q1 2012: € 3 million), driven by royalties for the Process Solutions’ pharmaceutical-chemical products. The division’s primary growth contributor once again was the Process Solutions business unit, which markets products that are used in drug production, generating an organic increase in sales of 6.9% [...]
The Consumer Health division reported sales of € 116 million, an increase of 7.9% (Q1 2012: € 108 million). This reflected organic growth of 9.3% and a 1.4% decrease from changes in foreign exchange rates. The healthy organic increase was apparent across all regions, with sales in Europe benefiting particularly from good development of cough & cold treatments as a result of the unusually long winter period. In addition, growth was further stimulated by increased focus on strategic brands, like Bion® and Femibion®. The efficiency improvements Consumer Health initiated last year are well on track and are beginning to generate visible improvements to the [...]
At the end of the first quarter of 2013, Merck had 38,311 employees worldwide, compared to 38,847 on December 31, 2012. Merck Group | Number of employees as of March 31: 38,311 From a regional perspective, the Emerging Markets region, which comprises Latin America and Asia excluding Japan, generated the strongest organic sales growth, expanding sales by 11.5% to € 924 million (Q1 2012: € 845 million). This increase was due especially to the performance of the Merck Serono and Performance Materials divisions. The proportion of Group sales accounted for by this region thus increased to 35% (Q1 2012: 33%). In North America, sales grew organically by 5.6% to € [...]
